scPharmaceuticals/$SCPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About scPharmaceuticals
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.
Ticker
$SCPH
Sector
Primary listing
Employees
163
Headquarters
Website
SCPH Metrics
BasicAdvanced
$302M
-
-$1.77
0.39
-
Price and volume
Market cap
$302M
Beta
0.39
52-week high
$6.28
52-week low
$1.94
Average daily volume
1.7M
Financial strength
Current ratio
3.854
Quick ratio
2.961
Long term debt to equity
-244.811
Total debt to equity
-246.05
Interest coverage (TTM)
-10.87%
Profitability
EBITDA (TTM)
-66.523
Gross margin (TTM)
68.46%
Net profit margin (TTM)
-183.55%
Operating margin (TTM)
-133.16%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-57.08%
Return on equity (TTM)
1,520.24%
Valuation
Price to revenue (TTM)
5.825
Price to book
-14.03
Price to tangible book (TTM)
-14.03
Price to free cash flow (TTM)
-4.418
Free cash flow yield (TTM)
-22.63%
Free cash flow per share (TTM)
-1.27
Growth
Revenue change (TTM)
107.79%
Earnings per share change (TTM)
13.31%
3-year earnings per share growth (CAGR)
15.62%
What the Analysts think about SCPH
Analyst ratings (Buy, Hold, Sell) for scPharmaceuticals stock.
Bulls say / Bears say
Net FUROSCIX revenue nearly doubled year-over-year to $16.0 million in Q2 2025, underscoring strong commercial traction as adoption accelerates across patient segments (GlobeNewswire).
The FDA approved the supplemental NDA expanding FUROSCIX's indication to include edema in chronic kidney disease patients on March 6, 2025, with a formal launch in April and immediate uptake by nephrologists, broadening the addressable market (GlobeNewswire).
The SCP-111 80mg/1mL FUROSCIX autoinjector program remains on track for sNDA submission in Q3 2025, promising to reduce administration time from five hours to under ten seconds and enhance patient convenience (GlobeNewswire).
Net loss widened to $18.0 million in Q2 2025 from $17.1 million in Q2 2024, reflecting ongoing high cash burn despite revenue growth (GlobeNewswire).
The gross-to-net discount increased to 27% in Q2 2025 from 23% in Q1 2025, indicating rising sales price concessions that could pressure future margins (GlobeNewswire).
Selling, general and administrative expenses surged 21% year-over-year to $21.2 million in Q2 2025, reflecting escalating operating costs that may delay profitability (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 22 Aug 2025.
SCPH Financial Performance
Revenues and expenses
SCPH Earnings Performance
Company profitability
SCPH News
AllArticlesVideos
SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH
Business Wire1 day ago
SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH
Business Wire3 weeks ago
SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for scPharmaceuticals stock?
scPharmaceuticals (SCPH) has a market cap of $302M as of September 17, 2025.
What is the P/E ratio for scPharmaceuticals stock?
The price to earnings (P/E) ratio for scPharmaceuticals (SCPH) stock is 0 as of September 17, 2025.
Does scPharmaceuticals stock pay dividends?
No, scPharmaceuticals (SCPH) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next scPharmaceuticals dividend payment date?
scPharmaceuticals (SCPH) stock does not pay dividends to its shareholders.
What is the beta indicator for scPharmaceuticals?
scPharmaceuticals (SCPH) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.